Literature DB >> 15162375

Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence.

Wendy J Huss1, Christopher W Gregory, Gary J Smith.   

Abstract

BACKGROUND: Neuroendocrine (NE) cell differentiation is proposed to facilitate prostate cancer (CaP) recurrence following androgen deprivation through secretion by NE cells of growth factors and neuropeptides that support survival and proliferation of CaP cells and vasculature.
METHODS: The effect of androgen deprivation on NE differentiation and tumor cell proliferation in the CWR22 model of human CaP was determined by immunohistochemical analysis of the NE cell marker synaptophysin and the cell proliferation marker Ki67.
RESULTS: A significant increase in the number of NE cells was observed in CWR22 tumors between 28 and 66 days after castration compared to intact mice, that preceded the increase in tumor cell proliferation that began 70 days after androgen deprivation heralding recurrence. There was a significant positive correlation between the number of tumor-associated NE cells and proliferating CaP cells in tumors from mice after 28-34 days of androgen withdrawal.
CONCLUSION: In the CWR22 model, androgen deprivation induces an increase in tumor-associated NE cells prior to increased tumor cell proliferation, with NE cells possibly promoting tumor survival and recurrent disease. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162375     DOI: 10.1002/pros.20032

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  Protocadherin-PC promotes androgen-independent prostate cancer cell growth.

Authors:  Stephane Terry; Luis Queires; Sixtina Gil-Diez-de-Medina; Min-Wei Chen; Alexandre de la Taille; Yves Allory; Phuong-Lan Tran; Claude C Abbou; Ralph Buttyan; Francis Vacherot
Journal:  Prostate       Date:  2006-07-01       Impact factor: 4.104

2.  Neuroendocrine differentiation of prostate cancer.

Authors:  Zhen Li; Clark J Chen; Jason K Wang; Elaine Hsia; Wei Li; Jill Squires; Yin Sun; Jiaoti Huang
Journal:  Asian J Androl       Date:  2013-03-18       Impact factor: 3.285

3.  LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling.

Authors:  Dongxia Ge; Allen C Gao; Qiuyang Zhang; Sen Liu; Yun Xue; Zongbing You
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

Review 4.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

5.  Biology and evolution of poorly differentiated neuroendocrine tumors.

Authors:  David S Rickman; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Med       Date:  2017-06-06       Impact factor: 53.440

6.  The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells.

Authors:  Seung-Keun Hong; Jin-Hwan Kim; Ming-Fong Lin; Jong-In Park
Journal:  Exp Cell Res       Date:  2011-08-16       Impact factor: 3.905

7.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

8.  Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.

Authors:  Paula Sotomayor; Alejandro Godoy; Gary J Smith; Wendy J Huss
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

Review 9.  The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities.

Authors:  Jianfei Qi; Maurizio Pellecchia; Ze'ev A Ronai
Journal:  Oncotarget       Date:  2010-09

Review 10.  Oncogenic activation of androgen receptor.

Authors:  Hsing-Jien Kung; Christopher P Evans
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.